Brief: Cogent Biosciences - Enters Commercial Supply Agreement With Hovione On Sept 1, 2026 - SEC Filing
02/09/2026 21:19
BRIEF-Cogent Biosciences - Enters Commercial Supply Agreement With Hovione On Sept 1, 2026 - SEC Filing Sept 2 (Reuters) - Cogent Biosciences, Inc. COGT.O:
COGENT BIOSCIENCES - ENTERS COMMERCIAL SUPPLY AGREEMENT WITH HOVIONE ON SEPT 1, 2026 - SEC FILING
COGENT BIOSCIENCES - TO PURCHASE MINIMUM PERCENTAGES OF BEZUCLASTINIB PRODUCTS FROM HOVIONE - SEC FILING
COGENT BIOSCIENCES - AGREEMENT EFFECTIVE FOR FIVE-YEAR TERM WITH AUTOMATIC TWO-YEAR RENEWALS - SEC FILING
Source text: []
Further company coverage: COGT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cogent Biosciences
See all newsBrief: Cogent Biosciences - Enters Commercial Supply Agreement With Hovione On Sept 1, 2026 - SEC Filing
Brief: Cogent Biosciences - May Offer Up To $400 Million In Common Stock Through Guggenheim Securities
Cogent Biosciences Q2 net loss widens on higher expenses
Brief: Cogent Biosciences Q2 Net Income USD -96.405 Million
U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's